Transparency Document
NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V.1.2025
| Request Number | Guideline Page | Specific change request | Panel Decision | Comment | Institution Vote |
|---|---|---|---|---|---|
| 2740 |
CRIT-2
Testing Criteria Submission from Myriad Genetics, Ambry Genetics, Illumina Inc., Quest Diagnostics on 03-07-2024 |
We request that the age of breast cancer diagnosis that qualifies for genetic testing be raised to <65y to match the recently released American Society of Clinical Oncology - Society for Surgical Oncology (ASCO-SSO) guideline, which provides evidence-based recommendations on germline testing in patients with breast cancer1. Specifically:
- Page CRIT-2, second bullet (Personal history of breast cancer…):
|
Change not made, current language sufficient | Language on CRIT-3 (Testing may be considered) revised to include: Personal history of breast cancer ≤65 y not meeting any of the above criteria |
Yes: 13 No: 17 Abstain:0 Absent:4 |
| 4557 | CRIT-2 Submitted by AstraZeneca on 08-03-23 | In the table for testing criteria for high-penetrance breast cancer susceptibility genes, under the “personal history of breast cancer with specific features:” bullet - change “<50 y” to “<65 y” | Change not made, panel supported alternate language | Language on CRIT-3 (Testing may be considered) revised to include: Personal history of breast cancer ≤65 y not meeting any of the above criteria |
Yes: 13 No: 17 Abstain:0 Absent:4 |